Captopril Half-Life
The elimination half-life of captopril is less than 2 hours in patients with normal renal function, but is significantly prolonged in patients with renal impairment. 1
Normal Renal Function
In patients with normal renal function, captopril demonstrates the following pharmacokinetic parameters:
- Elimination half-life: approximately 2 hours (though an accurate determination suggests it is probably less than 2 hours) 1
- Apparent elimination half-life for total radioactivity in blood: less than 3 hours 1
- Peak blood levels occur at approximately 1 hour after oral administration 1
- Over 95% of the absorbed dose is eliminated in the urine within 24 hours 1
Research confirms these values, with studies showing an elimination half-life of approximately 1.7 hours in healthy subjects and patients with uncomplicated hypertension 2. Another comprehensive pharmacokinetic review reported the elimination half-life as approximately 2 hours in healthy volunteers 3.
Renal Impairment
In patients with renal impairment, retention of captopril occurs and the half-life is markedly prolonged 1. This is clinically significant because:
- The elimination half-life increases progressively with worsening renal function 4, 5
- In patients with severe renal impairment (creatinine clearance <30 mL/min), the half-life can be substantially extended 4
- One study found the biological half-life showed significant delay in chronic renal failure patients with average serum creatinine of 5.1 mg/dL 6
Clinical Implications
The prolonged half-life in renal impairment necessitates dose adjustment:
- Dose reduction is necessary in patients with renal failure 4
- Body clearance decreases from 5.2 mL/min/kg in mild renal failure to 1.6 mL/min/kg in hemodialysis patients 4
- Renal clearance falls from 2.2 mL/min/kg in mild impairment to 0.2 mL/min/kg in severe impairment 4
Important Caveat
While the half-life of unchanged captopril is relatively short, the antihypertensive effects persist for a longer period than does demonstrable inhibition of circulating ACE 1. This is likely due to captopril's metabolites (disulfide dimer and captopril-cysteine disulfide) which may serve as a reservoir of pharmacologically active drug through reversible interconversion 3, 5.